Tumor Profiling Market Size, Share & Forecast 2025-2033

Buy Now
Excel: 8 Hours
PDF: 24 Hours
May 2025
Pages: 200

FAQs

Tumor profiling is the process of analyzing the genetic, proteomic, and molecular characteristics of a tumor to determine the most effective personalized treatment plan. It helps in selecting targeted therapies, improving treatment outcomes, and reducing unnecessary side effects.

Key technologies include:

  • Next-Generation Sequencing (NGS)

  • Polymerase Chain Reaction (PCR)

  • Immunohistochemistry (IHC)

  • In Situ Hybridization (ISH)

  • Microarrays
    These technologies help identify mutations, biomarkers, and gene expressions crucial for cancer diagnostics and therapeutics.

The global tumor profiling market is projected to reach USD 9.92 billion by 2033, growing at a CAGR of 26.56% from 2025 to 2033. Growth is driven by rising cancer incidence, demand for precision medicine, and advancements in genomic technologies.

  • North America holds the largest share due to advanced healthcare infrastructure, government funding, and adoption of precision oncology.

  • Asia-Pacific is the fastest-growing region, propelled by increasing healthcare investments, cancer prevalence, and technological advancements.

Tumor profiling is widely used for:

  • Cancer diagnosis

  • Prognosis and disease monitoring

  • Treatment decision-making

  • Drug development
    It enables clinicians to tailor therapies based on individual tumor biology.

Leading companies include:

  • Illumina, Inc.

  • Thermo Fisher Scientific

  • QIAGEN

  • Caris Life Sciences

  • Guardant Health

  • HTG Molecular Diagnostics
    These companies focus on innovation, partnerships, and expanding their product pipelines.

Challenges:

  • High cost of profiling tests

  • Data interpretation complexity

  • Limited access in low-income regions

Opportunities:

  • Integration of AI and machine learning

  • Growing demand for personalized oncology

  • Expansion into emerging markets